Year-end Sale % OFF 
Abstract
Hepatocellular carcinoma (HCC) is the fifth-most common cancer and third leading cause of cancer-related deaths worldwide. Increasing evidence indicates that dysregulation of microRNAs is often observed in HCC, and has been extensively investigated in terms of cancer formation, progression, diagnosis, therapy, and prognosis. Recently, microRNA-326 (miR-326) has been demonstrated to play important roles in multiple types of human cancer. However, the expression pattern, clinical significance, roles and regulatory mechanisms of miR-326 in HCC have yet to be elucidated. In this study, miR-326 was frequently downregulated in HCC tissues and cell lines. Low miR-326 expression was significantly associated with the TNM stage, differentiation and lymph node metastasis of HCC patients. Further functional assays demonstrated that the recovered miR-326 expression inhibited HCC cell proliferation and invasion and activated cell apoptosis invitro. In addition, LIM and SH3 protein1 (LASP1) was identified as a direct target gene of miR-326 in HCC. Furthermore, LASP1 was upregulated in HCC tissues and cell lines. The expression level of LASP1 mRNA was inversely correlated with that of miR-326 in HCC tissues. Moreover, LASP1 silencing elicited effects similar to miR-326 overexpression on HCC cells, and LASP1 upregulation markedly reversed the effects of miR-326 overexpression on HCC cells. These results revealed that miR-326 suppressed the progression of HCC by directly targeting LASP1. Therefore, miR-326 may be used as a potential therapeutic target for the treatment of patients with HCC.
Highlights
Hepatocellular carcinoma (HCC), which is a dominant histological type of liver cancer, is the fifth-most common cancer and third leading cause of cancer-related deaths worldwide [1]
The results revealed that the miR-326 expression was significantly lower in the HCC tissues than in the adjacent non-cancerous liver tissues (Fig. 1A, P
We found that the miR-326 expression was lower in the HCC cell lines than in LO2 (Fig. 1B, P
Summary
Hepatocellular carcinoma (HCC), which is a dominant histological type of liver cancer, is the fifth-most common cancer and third leading cause of cancer-related deaths worldwide [1]. Despite current advancements in diagnostic methods and treatment strategies, the average survival of HCC patients has not improved significantly [3]. High recurrence rate and metastasis are the major causes of cancer-related deaths in patients with HCC [4,5]. The majority of HCC patients are diagnosed in late or end stages and deprived of optimal treatments [6]. The molecular mechanisms involved in the formation and progression of HCC should be elucidated and efficient therapeutic targets for patients with this malignancy should be developed
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
